VVEO3 Stock Overview
Engages in the distribution of hospital materials, medicines, and nutrition products in Brazil.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
CM Hospitalar S/A Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$1.99 |
| 52 Week High | R$16.29 |
| 52 Week Low | R$1.75 |
| Beta | 0.22 |
| 11 Month Change | -9.13% |
| 3 Month Change | -16.03% |
| 1 Year Change | -87.29% |
| 33 Year Change | -90.77% |
| 5 Year Change | n/a |
| Change since IPO | -90.87% |
Recent News & Updates
Recent updates
There Is A Reason CM Hospitalar S/A's (BVMF:VVEO3) Price Is Undemanding
Oct 17
Capital Allocation Trends At CM Hospitalar S/A (BVMF:VVEO3) Aren't Ideal
Jul 30CM Hospitalar S/A (BVMF:VVEO3) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough
Jun 25CM Hospitalar S/A (BVMF:VVEO3) Not Doing Enough For Some Investors As Its Shares Slump 49%
May 11CM Hospitalar S/A (BVMF:VVEO3) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 01Analysts Are Updating Their CM Hospitalar S/A (BVMF:VVEO3) Estimates After Its Annual Results
Mar 29Why Investors Shouldn't Be Surprised By CM Hospitalar S/A's (BVMF:VVEO3) 28% Share Price Plunge
Mar 27Here's Why CM Hospitalar S/A (BVMF:VVEO3) Has A Meaningful Debt Burden
Jan 15Here's What To Make Of CM Hospitalar S/A's (BVMF:VVEO3) Decelerating Rates Of Return
Dec 14CM Hospitalar S/A (BVMF:VVEO3) Has More To Do To Multiply In Value Going Forward
Jun 07Returns On Capital Signal Tricky Times Ahead For CM Hospitalar S/A (BVMF:VVEO3)
Jan 16Be Wary Of CM Hospitalar S/A (BVMF:VVEO3) And Its Returns On Capital
Aug 31Statutory Earnings May Not Be The Best Way To Understand CM Hospitalar S/A's (BVMF:VVEO3) True Position
May 17Pinning Down CM Hospitalar S/A's (BVMF:VVEO3) P/E Is Difficult Right Now
Dec 09Shareholder Returns
| VVEO3 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | 11.8% | -0.6% | 0.7% |
| 1Y | -87.3% | 0.7% | 9.6% |
Return vs Industry: VVEO3 underperformed the BR Healthcare industry which returned 0.8% over the past year.
Return vs Market: VVEO3 underperformed the BR Market which returned 9.8% over the past year.
Price Volatility
| VVEO3 volatility | |
|---|---|
| VVEO3 Average Weekly Movement | 10.7% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 9.1% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: VVEO3's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: VVEO3's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 6,000 | Leonardo Byrro | www.mafrasaude.com.br |
CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers ophthalmic agent, adrenergic and thrombopoietin agonist, aminoglycosides, painkiller, anesthetics, receptor antagonist, anti-hemorrhoidal, antihypertensives, systemic antihistamine, and orthopedic therapy materials; and anti-inflammatories, anti-TNF, antacid, antiandrogen, antianemic, anti-asthmatic, antibiotic, anticoagulant, anticonvulsant, monoclonal antibody, anti-growth, antidepressant, antidiabetic, antidiuretic, antidote, antiemetics and antinauseants, anti-migraine, antiepileptics, antiestrogens, antifibrinolytic, antiflatulent, antifungal, antihemorrhagic, antimicrobial, antineoplastics, antiparathyroid drugs, antiparkinsonian, antipsychotic, systemic antipsoriasis, antirheumatics, anti-varicose, and antiviral medicines. It also provides beta blocker, carbohydrate, cycloplegic, contraceptive, contrast, special control, corticosteroid, topical debrider, diuretic, electrolyte, pancreatic enzyme, erythropoietin, uterine and cardiac stimulant, growth factor, granulocyte colony stimulating factor, gastroprokinetic, systemic hemostatic, heparins, hepatoprotector and lipotropic, hormone, adeno-pituitary and growth hormone, immunoglobulin, immunosuppressant, labor inducer, proton pump and phosphodiesterase inhibitor, bone resorption inhibitor, platelet aggregation inhibitor, adenosine diphosphate receptor antagonist, proton pump and interleukin inhibitor, proprotein convertase subtilisin/kexin type 9 inhibitor, and calcium reabsorption inhibitor medicines.
CM Hospitalar S/A Fundamentals Summary
| VVEO3 fundamental statistics | |
|---|---|
| Market cap | R$633.80m |
| Earnings (TTM) | R$182.88m |
| Revenue (TTM) | R$11.46b |
3.5x
P/E Ratio0.1x
P/S RatioIs VVEO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVEO3 income statement (TTM) | |
|---|---|
| Revenue | R$11.46b |
| Cost of Revenue | R$9.82b |
| Gross Profit | R$1.64b |
| Other Expenses | R$1.46b |
| Earnings | R$182.88m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 14.34% |
| Net Profit Margin | 1.60% |
| Debt/Equity Ratio | 119.8% |
How did VVEO3 perform over the long term?
See historical performance and comparison